![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication July 21, 2006.
Revised September 16, 2006.
Accepted for publication September 18, 2006.
We used pharmacological agents and genetic methods to determine whether the potent A3 adenosine receptor (AR) agonist 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (Cl-IB-MECA) protects against myocardial ischemia/reperfusion injury in mice via the A3AR or via interactions with other AR subtypes. Pretreating wild-type (WT) mice with Cl-IB-MECA reduced myocardial infarct size induced by 30 min of coronary occlusion and 24 h of reperfusion at doses (30 and 100 µg/kg) that concomitantly reduced blood pressure and stimulated systemic histamine release. The A3AR-selective antagonist MRS 1523, but not the A2AAAR antagonist ZM 241385, blocked the reduction in infarct size provided by Cl-IB-MECA, suggesting a mechanism involving the A3AR. To further examine the selectivity of Cl-IB-MECA, we assessed its cardioprotective effectiveness in A3AR gene 'knock-out' (A3KO) mice. Cl-IB-MECA did not reduce myocardial infarct size in A3KO mice in vivo and did not protect isolated perfused hearts obtained from A3KO mice from injury induced by global ischemia and reperfusion. Additional studies using WT mice treated with compound 48/80 to deplete mast cell contents excluded the possibility that Cl-IB-MECA was cardioprotective by releasing mediators from mast cells. These data demonstrate that Cl-IB-MECA protects against myocardial ischemia/reperfusion injury in mice principally by activating the A3AR.
Key words:
adenosine, heart, infarction, ischemia, receptors, reperfusion
This article has been cited by other articles:
![]() |
B. A. Rothermel and J. A. Hill Adenosine A3 Receptor and Cardioprotection: Enticing, Enigmatic, Elusive Circulation, October 21, 2008; 118(17): 1691 - 1693. [Full Text] [PDF] |
||||
![]() |
Z. Lu, J. Fassett, X. Xu, X. Hu, G. Zhu, J. French, P. Zhang, J. Schnermann, R. J. Bache, and Y. Chen Adenosine A3 Receptor Deficiency Exerts Unanticipated Protective Effects on the Pressure-Overloaded Left Ventricle Circulation, October 21, 2008; 118(17): 1713 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. van der Hoeven, T. C. Wan, and J. A. Auchampach Activation of the A3 Adenosine Receptor Suppresses Superoxide Production and Chemotaxis of Mouse Bone Marrow Neutrophils Mol. Pharmacol., September 1, 2008; 74(3): 685 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Wan, Z.-D. Ge, A. Tampo, Y. Mio, M. W. Bienengraeber, W. R. Tracey, G. J. Gross, W.-M. Kwok, and J. A. Auchampach The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 234 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Ansari, A. Nadeem, S. L. Tilley, and S. J. Mustafa Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3448 - H3455. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zheng, R. Wang, E. Zambraski, D. Wu, K. A. Jacobson, and B. T. Liang Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3685 - H3691. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhu, P. A. Hofmann, and J. K. Buolamwini Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2921 - H2926. [Abstract] [Full Text] [PDF] |
||||